Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19 Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT04232826
What this trial is testing

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Non-Hodgkin Lymphoma
Juventas Cell Therapy Ltd. 9
Testing effectiveness (Phase 2)Looking for participantsNCT07077512
What this trial is testing

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Large B Cell Diffuse LymphomaMantle Cell Lymphoma (MCL)Follicular Lymphoma ( FL)
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Looking for participantsNCT06220487
What this trial is testing

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL

Who this might be right for
Acute Lymphoblastic LeukemiaPhiladelphia ChromosomePhiladelphia-Positive ALL+2 more
Nanfang Hospital, Southern Medical University 67
Early research (Phase 1)UnknownNCT05420493
What this trial is testing

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon Hodgkin Lymphoma
Chongqing Precision Biotech Co., Ltd 54
Testing effectiveness (Phase 2)Ended earlyNCT05348889
What this trial is testing

First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

Who this might be right for
Non-Hodgkin's Lymphoma (disorder)Acute Lymphoid Leukemia, Disease (disorder)
Chimagen Biosciences, Ltd 7
Early research (Phase 1)UnknownNCT03030976
What this trial is testing

CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)

Who this might be right for
Systemic Lupus Erythematosus (SLE)
Shanghai GeneChem Co., Ltd. 5
Early research (Phase 1)UnknownNCT02799550
What this trial is testing

Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL

Who this might be right for
Leukemia
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 10
Not applicableStudy completedNCT05440409
What this trial is testing

CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

Who this might be right for
Leukemia, Acute LymphoblasticLymphoblastic Leukemia, Acute, Childhood
National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Looking for participantsNCT06213636
What this trial is testing

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Who this might be right for
Acute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in RelapseNon-Hodgkin Lymphoma, B-cell+4 more
Essen Biotech 75
Early research (Phase 1)Active Not RecruitingNCT03853616
What this trial is testing

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Who this might be right for
Acute Lymphoblastic Leukemia RecurrentB-cell Lymphoma RecurrentB-cell Lymphoma Refractory+2 more
Miltenyi Biomedicine GmbH 48
Early research (Phase 1)UnknownNCT04943016
What this trial is testing

CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies

Who this might be right for
Relapsed/Refractory B-Cell Malignancies
National Taiwan University Hospital 12
Testing effectiveness (Phase 2)Looking for participantsNCT07244406
What this trial is testing

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

Who this might be right for
B-ALL
Hebei Senlang Biotechnology Inc., Ltd. 59
Testing effectiveness (Phase 2)WithdrawnNCT04029038
What this trial is testing

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Who this might be right for
CD19 PositiveCD22 PositiveMinimal Residual Disease+7 more
M.D. Anderson Cancer Center
Early research (Phase 1)Not Yet RecruitingNCT07043218
What this trial is testing

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Shanghai Tongji Hospital, Tongji University School of Medicine 36
Large-scale testing (Phase 3)Not Yet RecruitingNCT07723911
What this trial is testing

Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL

Who this might be right for
Precursor B-cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 212
Very early researchUnknownNCT06393335
What this trial is testing

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
The Children's Hospital of Zhejiang University School of Medicine 36
Testing effectiveness (Phase 2)UnknownNCT02892695
What this trial is testing

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)UnknownNCT02349698
What this trial is testing

A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Who this might be right for
LeukemiaLymphoma
Southwest Hospital, China 45
Early research (Phase 1)UnknownNCT04888442
What this trial is testing

Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd 18
Early research (Phase 1)Looking for participantsNCT06875063
What this trial is testing

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Who this might be right for
Non-hodgkin LymphomaRefractory LymphomaChimeric Antigen Receptor T-cell
The First Affiliated Hospital of Xiamen University 45
Next Page